September 10, 2015

RAS mutation status influence on the treatment effect of panitumumab has been evaluated in a recent prospective-retrospective multicenter analysis (Peeters, M et al.). This retrospective-prospective analysis of a phase 3 randomized trial examined the influence of extended RAS mutation evaluation on second-line efficacy of fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus panitumumab or FOLFIRI alone in 1186 […]

Hereditary and Familial Prostate Cancer 3 gene panel Affected patients of Hereditary Prostate Cancer families should consider being tested for the most frequently inherited genetic defects identified in Familial Prostate Cancer: BRCA2, PALB2, and ATM germline mutations.